Most common (≥10%) treatment-related adverse events (maximum grade, all cycles)
| Veliparib dose level | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total number of patients with event | 10 mg N = 7 | 20 mg N = 9 | 40 mg N = 12 | 50 mg N = 7 | |||||
| Adverse event | N = 35 (%) | All (%) | Gr ≥ 3 (%) | All (%) | Gr ≥ 3 (%) | All (%) | Gr ≥ 3 (%) | All (%) | Gr ≥ 3 (%) |
| Diarrhea | 22 (63) | 5 (71) | 1 (14) | 5 (56) | 1 (11) | 8 (67) | — | 4 (57) | 1 (14) |
| Fatigue | 21 (60) | 5 (71) | 1 (14) | 5 (56) | 2 (22) | 6 (50) | — | 5 (71) | — |
| Nausea | 21 (60) | 4 (57) | — | 7 (78) | — | 6 (50) | — | 4 (57) | — |
| Leukopenia | 17 (49) | 4 (57) | 3 (43) | 4 (44) | 1 (11) | 4 (33) | 2 (17) | 5 (71) | 2 (29) |
| Neutropenia | 17 (49) | 4 (57) | 2 (29) | 4 (44) | 2 (22) | 5 (42) | 2 (17) | 4 (57) | 3 (43) |
| Anemia | 13 (37) | 4 (57) | 1 (14) | 1 (11) | — | 5 (42) | — | 3 (43) | — |
| Anorexia | 11 (31) | 3 (43) | — | 1 (11) | — | 4 (33) | — | 3 (43) | — |
| Vomiting | 9 (26) | 2 (29) | — | 3 (33) | — | 3 (25) | — | 1 (14) | — |
| Alopecia | 7 (20) | 1 (14) | — | 1 (11) | — | 4 (33) | — | 1 (14) | — |
| Lymphopenia | 6 (17) | 2 (29) | 2 (29) | 1 (11) | 1 (11) | 3 (25) | — | — | — |
| Dehydration | 5 (14) | 1 (14) | 1 (14) | 2 (22) | — | 1 (8) | — | 1 (14) | — |
| Hypoalbuminemia | 5 (14) | 1 (14) | — | 1 (11) | — | 3 (25) | — | — | — |
| Abdominal pain | 4 (11) | 1 (14) | — | 1 (11) | — | 1 (8) | — | 1 (14) | — |